What is Serán?
Serán operates at the forefront of pharmaceutical innovation, employing a science-first methodology and advanced technologies to empower its healthcare clientele. The company's core mission is to accelerate the discovery and development of novel medicines, ultimately aiming to enhance patient health outcomes. This focus positions Serán as a key player in the competitive drug development sector, attracting substantial backing for its ambitious goals.
How much funding has Serán raised?
Serán has raised a total of $200.3M across 2 funding rounds:
Debt
$350K
Other Financing Round
$200M
Debt (2020): $350K with participation from PPP
Other Financing Round (2024): $200M led by Vivo Capital and Bain Capital
Key Investors in Serán
Vivo Capital
Vivo Capital, founded in 1996 and headquartered in Palo Alto, California, is a global healthcare investment firm focused on private and public equity as well as venture capital.
Bain Capital
Founded in 1984, Bain Capital is one of the worlds leading private investment firms committed to creating lasting impact. The firm's Special Situations team specializes in capital solutions that offer companies flexible funding tailored to their specific needs, supported by robust operational, strategic, and financial value-add services.
What's next for Serán?
The recent major strategic investment signifies a pivotal moment for Serán, likely enabling the company to scale its operations, expand its research and development pipeline, and potentially forge new strategic partnerships. This infusion of capital is expected to fuel further innovation in medicine discovery and development, reinforcing Serán's commitment to improving global healthcare. The company is poised for significant growth and impact in the coming years.
See full Serán company page
